CO2021000506A2 - Soluciones de complejos de radionúclidos estables y concentradas - Google Patents

Soluciones de complejos de radionúclidos estables y concentradas

Info

Publication number
CO2021000506A2
CO2021000506A2 CONC2021/0000506A CO2021000506A CO2021000506A2 CO 2021000506 A2 CO2021000506 A2 CO 2021000506A2 CO 2021000506 A CO2021000506 A CO 2021000506A CO 2021000506 A2 CO2021000506 A2 CO 2021000506A2
Authority
CO
Colombia
Prior art keywords
stable
complex solutions
radionuclide complex
pharmaceutical product
concentrated
Prior art date
Application number
CONC2021/0000506A
Other languages
English (en)
Inventor
Daniela Chicco
Donato Barbato
Palo Francesco De
Lorenza Fugazza
Maurizio Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by Advanced Accelerator Applications Sa filed Critical Advanced Accelerator Applications Sa
Publication of CO2021000506A2 publication Critical patent/CO2021000506A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La presente invención se refiere a soluciones de complejos de radionúclidos de alta concentración y de alta estabilidad química, que permiten su uso como producto farmacéutico para fines de diagnóstico y/o terapéuticos. La estabilidad del producto farmacéutico se logra mediante por lo menos un estabilizador contra la degradación radiolítica. Se encontró que el uso de dos estabilizadores introducidos durante el proceso de fabricación en diferentes etapas fue una ventaja particular.
CONC2021/0000506A 2018-07-25 2021-01-20 Soluciones de complejos de radionúclidos estables y concentradas CO2021000506A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
CO2021000506A2 true CO2021000506A2 (es) 2021-04-19

Family

ID=63794577

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000506A CO2021000506A2 (es) 2018-07-25 2021-01-20 Soluciones de complejos de radionúclidos estables y concentradas

Country Status (13)

Country Link
EP (1) EP3826686A1 (es)
JP (2) JP7402218B2 (es)
KR (2) KR20240033296A (es)
CN (1) CN112584875A (es)
AU (3) AU2018433575B2 (es)
BR (1) BR112021001148A2 (es)
CA (1) CA3153630A1 (es)
CO (1) CO2021000506A2 (es)
DE (1) DE202018006567U1 (es)
IL (1) IL280314A (es)
MX (1) MX2021000805A (es)
SG (1) SG11202100645XA (es)
WO (1) WO2020021322A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2023100852A1 (ja) * 2021-11-30 2023-06-08 日本メジフィジックス株式会社 安定化放射性医薬組成物
WO2023148680A1 (en) * 2022-02-04 2023-08-10 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
CA2346448A1 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
JP4575667B2 (ja) 2002-03-08 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬として有用な大環状化合物
SI1482932T1 (sl) 2002-03-13 2010-02-26 Array Biopharma Inc N3-alkilirani derivati benzimidazola kot inhibitorji mek
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
SG144160A1 (en) * 2003-07-24 2008-07-29 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
WO2008009444A1 (en) * 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
EP3534969A4 (en) * 2016-11-04 2020-07-01 Clarity Pharmaceuticals Ltd FORMULAS FOR RADIATION THERAPY AND DIAGNOSTIC IMAGING

Also Published As

Publication number Publication date
CA3153630A1 (en) 2020-01-30
KR20240033296A (ko) 2024-03-12
KR20210035855A (ko) 2021-04-01
CN112584875A (zh) 2021-03-30
JP2023117417A (ja) 2023-08-23
DE202018006567U1 (de) 2021-02-22
MX2021000805A (es) 2021-05-12
JP7402218B2 (ja) 2023-12-20
WO2020021322A1 (en) 2020-01-30
BR112021001148A2 (pt) 2021-04-20
JP2022501313A (ja) 2022-01-06
EP3826686A1 (en) 2021-06-02
AU2022203683B2 (en) 2023-12-21
IL280314A (en) 2021-03-25
SG11202100645XA (en) 2021-02-25
AU2018433575A1 (en) 2021-02-11
KR102643582B1 (ko) 2024-03-05
AU2024201217A1 (en) 2024-03-14
AU2018433575B2 (en) 2022-07-07
AU2022203683A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
CO2021000506A2 (es) Soluciones de complejos de radionúclidos estables y concentradas
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
ECSP20021913A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2018002920A1 (es) Nuevos derivados de pirazolopirimidina
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
TR201908296T4 (tr) Karbi̇dopa ve l-dopa ön i̇laçlari ve parki̇nson hastaliğinin tedavi̇ edi̇lmesi̇nde bunlarin kullanimi
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
AR105712A1 (es) Composiciones de insulina de rápida acción
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR119655A1 (es) Soluciones de complejos de radionúclidos estables y concentradas
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
SG10201811574YA (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
UY35439A (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
AU2017356887A8 (en) sGC stimulators
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
AR107298A1 (es) Método de purificación
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа